| Chronic rhinosinusitis with multiple nasal polyps
Nucala vs Tezspire
Side-by-side clinical, coverage, and cost comparison for chronic rhinosinusitis with multiple nasal polyps.Deep comparison between: Nucala vs Tezspire with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTezspire has a higher rate of injection site reactions vs Nucala based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tezspire but not Nucala, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Nucala
Tezspire
At A Glance
SC injection
Every 4 weeks
IL-5 antagonist
SC injection
Every 4 weeks
TSLP blocker
Indications
- Asthma
- Chronic rhinosinusitis with multiple nasal polyps
- Chronic Obstructive Airway Disease
- Eosinophilic granulomatosis with polyangiitis
- Hypereosinophilic syndrome
- Asthma
- Chronic rhinosinusitis with multiple nasal polyps
Dosing
Asthma (>=12 years), Chronic rhinosinusitis with multiple nasal polyps, Chronic Obstructive Airway Disease 100 mg SC once every 4 weeks.
Asthma (6-11 years) 40 mg SC once every 4 weeks.
Eosinophilic granulomatosis with polyangiitis, Hypereosinophilic syndrome 300 mg SC once every 4 weeks, administered as 3 separate 100 mg injections at least 5 cm apart.
Asthma, Chronic rhinosinusitis with multiple nasal polyps 210 mg administered subcutaneously once every 4 weeks.
Contraindications
- History of hypersensitivity to mepolizumab or excipients in the formulation
- Known hypersensitivity to tezepelumab-ekko or any of its excipients
Adverse Reactions
Most common (>=3%) headache, injection site reaction, back pain, fatigue, oropharyngeal pain, arthralgia, diarrhea, urinary tract infection, cough, pruritus, eczema
Serious herpes zoster
Postmarketing hypersensitivity reactions including anaphylaxis
Most common (>=3%) Nasopharyngitis, upper respiratory tract infection, pharyngitis, arthralgia, back pain, epistaxis, influenza, injection site reaction
Serious Serious cardiac adverse events (incidence rate 1.08 per 100 patient-years in TEZSPIRE vs 0.21 in placebo in long-term extension trial)
Postmarketing Anaphylaxis
Pharmacology
Mepolizumab is an IL-5 antagonist (IgG1 kappa) that binds IL-5 with high affinity, blocking its binding to the alpha chain of the IL-5 receptor complex on eosinophils, thereby inhibiting IL-5 signaling and reducing eosinophil production and survival.
TSLP blocker; tezepelumab-ekko is a human monoclonal antibody (IgG2lambda) that binds human thymic stromal lymphopoietin (TSLP) and blocks its interaction with the heterodimeric TSLP receptor, thereby reducing inflammatory biomarkers including blood eosinophils, IgE, FeNO, IL-5, and IL-13.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Nucala
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (11/12) · Qty limit (11/12)
Tezspire
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Nucala
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (6/8) · Qty limit (6/8)
Tezspire
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (4/8) · Qty limit (0/8)
Humana
Nucala
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Tezspire
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Asthma - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Asthma - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
NucalaView full Nucala profile
TezspireView full Tezspire profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.